Treatment of schizophrenia in the 21st Century: Beyond the neurotransmitter hypothesis

Expert Review of Neurotherapeutics

Volumn 9, Issue 1, 2009, Pages 47-54

  Rogers, Donald P ^a   Goldsmith, Carroll Ann W ^b  

^a State Office of Pharmacy Services   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Autoantibody; Autoimmunity; Etiology; Immunosuppressant; Immunosuppressive therapy; Schizophrenia

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CELECOXIB; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MOOD STABILIZER; NEUROTRANSMITTER; OLANZAPINE; PALIPERIDONE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; ZIPRASIDONE;

ANTIBODY TITER; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LEUKOPENIA; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION;

ANTIPSYCHOTIC AGENTS; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; NEUROTRANSMITTER AGENTS; SCHIZOPHRENIA;

EID: 58149230876     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.9.1.47     Document Type: Review

References (72)

1. Lehmann HE, Ban TA. The history of the psychopharmacology of schizophrenia. Can. J. Psychiatry 42(2), 152-162 (1997).
2. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 24(1), 62-67 (1988).
3. Lehmann-Facius H. Uber die liquordiagnose der schizophrenien. Klin. Wochenschr. 16, 1646-1648 (1937).
4. Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol. Psychiatry 40(9), 825-833 (1996).
5. Mazeh D, Sirota P, Patya M, Novogrodsky A. Antibodies to neuroblastoma cell line proteins in patients with schizophrenia. J. Neuroimmunol. 84(2), 218-222 (1998).
6. von Kirchbach A, Fischer EG, Kornhuber HH. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients (short note). J. Neural Transm. 70(1-2), 175-179 (1987).
7. Stevens A, Weller M. Ganglioside antibodies in schizophrenia and major depression. Biol. Psychiatry 32(8), 728-730 (1992).
8. Smith DA, Germolec DR. Introduction to immunology and autoimmunity. Environ. Health Perspect. 107(Suppl. 5), 661-665 (1999).
9. Levy-Soussan P, Barbouche R, Poirier MF, Galinowski A, Loo H, Avrameas S. A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics. Biol. Psychiatry 35(2), 135-138 (1994).
10. Levy-Soussan P, Berneman A, Poirier MF et al. Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals. J. Psychiatry Neurosci. 21(2), 89-95 (1996).
11. Ganguli R, Rabin BS, Brar JS. Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol. Psychiatry 32(8), 735-738 (1992).
12. Chengappa KN, Ganguli R, Yang ZW, Shurin G, Brar JS, Rabin BS. Impaired mitogen (PHA) responsiveness and increased autoantibodies in caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol. Psychiatry 37(8), 546-549 (1995).
13. Sirota P, Firer MA, Schild K et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol. Psychiatry 33(6), 450-455 (1993).
14. Chengappa KN, Ganguli R, Ulrich R et al. The prevalence of autoantibodies among right and left handed schizophrenic patients and control subjects. Biol. Psychiatry 32(9), 803-811 (1992).
15. Chengappa KN, Ganguli R, Yang ZW, Brar JS, Li L, Rabin BS. Left-handed first-episode, neuroleptic-naive schizophrenic patients have a higher prevalence of autoantibodies. Schizophr. Res. 8(1), 75-80 (1992).
16. Sirota P, Firer M, Schild K et al. Increased anti-sm antibodies in schizophrenic patients and their families. Prog. Neuropsychopharmacol. Biol. Psychiatry 17(5), 793-800 (1993).
17. Firer M, Sirota P, Schild K, Elizur A, Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J. Clin. Immunol. 14(1), 73-78 (1994).
18. Wang XF, Wang D, Zhu W, Delrahim KK, Dolnak D, Rapaport MH. Studies characterizing 60 kDa autoantibodies in subjects with schizophrenia. Biol. Psychiatry 53(5), 361-375 (2003).
19. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am. J. Psychiatry 156(7), 1103-1104 (1999).
20. Schwarz MJ, Riedel M, Gruber R, Muller N, Ackenheil, M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 248(6), 282-288 (1998).
21. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr. Res. 52(1-2), 127-135 (2001).
22. Shcherbakova IV, Siryachenk TM, Mazaeva NA, Kaleda VG, Krasnolobova SA, Klyushnik TP. Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J. Biol. Psychiatry 5(3), 143-148 (2004).
23. Kessler A, Shinitzky M. Platelets from schizophrenic patients bear autoimmune antibodies that inhibit dopamine uptake. Psychobiology 21(4), 299-306 (1993).
24. Sinyakov MS, Kessler B, Karp L, Weizman A, Kessler AR. Platelet-associated antibodies mediate protective autoimmune response in schizophrenia. Neuropsychobiology 48(1), 41-46 (2003).
25. Reichelt KL, Landmark J. Specific IgA antibody increases in schizophrenia. Biol. Psychiatry 37(6), 410-413 (1995).
26. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 14(1), 15-22 (1994).
27. Schott K, Schaefer JE, Richartz E et al. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res. 121(1), 51-57 (2003).
28. Tanaka S, Matsunaga H, Kimura M et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol. 141(1-2), 155-164 (2003).
29. Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr. Res. 12(2), 131-136 (1994).
30. Borda T, Gomez R, Berria MI, Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 45(2), 144-154 (2004).
31. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J. Immunol. 168(7), 3667-3674 (2002).
32. Ganguli R, Yang Z, Shurin G et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 51(1), 1-10 (1994).
33. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res. 87(2-3), 129-136 (1999).
34. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 57(2-3), 247-258 (2002).
35. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr. Res. 84(1), 180-182 (2006).
36. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 19(1), 75-83 (1995).
37. Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J. Psychiatr. Res. 41(1-2), 3-7 (2007).
38. Schwarz MJ, Kronig H, Riedel M et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 256(2), 72-76 (2006).
39. Berger A. Th1 and Th2 responses: what are they? BMJ 321(7258), 424 (2000).
40. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev. Neurother 7, 789-796 (2007).
41. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res. 44(2), 113-123 (1992).
42. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J. Autoimmun. 9(5), 661-666 (1996).
43. Satcher DS. Executive summary: a report of the surgeon general on mental health. Public Health Rep. 115(1), 89-101 (2000).
44. Lencz T, Morgan TV, Athansiou M et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol. Psychiatry 12, 572-580 (2007).
45. Chen X, Wang X, Hossain S et al. Interleukin 3 and schizophrenia: the impact of sex and family history. Mol. Psychiatry 12, 273-582 (2007).
46. Lencz T, Lambert C, DeRosse P et al. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc. Natl Acad. Sci. USA 104(50), 19942-19947 (2007).
47. Chen X, Kendler KS. Interleukin 3 and schizophrenia. Am. J. Psychiatry 165(1), 13-14 (2008).
48. Chowdari KV, Xu K, Zhang F et al. Immune related genetic polymorphisms and schizophrenia among the Chinese. Hum. Immunol. 62(7), 714-724 (2001).
49. Haider MZ, Zahid MA. Human leukocyte antigen-DQB1 alleles are not associated with schizophrenia in Kuwaiti Arabs. Psychiatry Clin. Neurosci. 58(3), 236-239 (2004).
50. Schwab SG, Hallmayer J, Freimann, J et al. Investigation of linkage and association/ linkage disequilibrium of HLA A-, DQA1-, DQB1-, and DRB1-alleles in 69 sib-pairand 89 trio-families with schizophrenia. Am. J. Med. Genet. 114(3), 315-320 (2002).
51. Glatt SJ, Everall IP, Kremen et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc. Natl Acad. Sci. USA 102(43), 15533-15538 (2005).
52. Debnath M, Das SK, Bera NK, Nayak CR, Chaudhuri TK. Genetic associations between delusional disorder and paranoid schizophrenia: a novel etiologic approach. Can. J. Psychiatry 51(6), 342-349 (2006).
53. Debnath M, Chaudhuri TK. The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: a novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med. Hypotheses 66(2), 286-293 (2006).
54. Laumbacher B, Muller N, Bondy B et al. Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients. J. Med. Genet. 40(3), 217-219 (2003).
55. Hawi Z, Gibson S, Straub RE, Walsh D, Kendler KS, Gill M. Schizophrenia and HLA: no association with PCR-SSOP typed classical loci in a large Irish familial sample. Am. J. Med. Genet. 88(4), 422-429 (1999).
56. Jacobsen LK, Mittleman BB, Kumra S et al. HLA antigens in childhood onset schizophrenia. Psychiatry Res. 78(3), 123-132 (1998).
57. Matsumoto S, Sasaki T, Imamura A et al. HLA class I distribution in Japanese patients with schizophrenia. Am. J. Med. Genet. 114(1), 42-45 (2002).
58. Tochigi M, Ohashi J, Umekage T et al. Human leukocyte antigen-A specificities and its relation with season of birth in Japanese patients with schizophrenia. Neurosci. Lett. 329(2), 201-204 (2002).
59. Ozcan ME, Taskin R, Banoglu R, Babacan M, Tuncer E. HLA antigens in schizophrenia and mood disorders. Biol. Psychiatry 39(10), 891-895 (1996).
60. Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr. Opin. Immunol. 17(5), 526-531 (2005).
61. McAllister CG, Rapaport MH, Pickar D, Paul SM. Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch. Gen. Psychiatry 46(10), 956-957 (1989).
62. Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 37(1), 75-86 (1997).
63. Hinze-Selch D Becker EW, Stein GM et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 19(2), 114-122 (1998).
64. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 65(7), 940-947 (2004).
65. Bilici M, Tekelioglu Y, Efendioglu S, Ovali E, Ulgen M. The influence of olanzapine on immune cells in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(3), 483-485 (2003).
66. Muller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 159(6), 1029-1034 (2002).
67. Levine J, Gutman J, Feraro R et al. Side effect profile of azathioprine in the treatment of chronic schizophrenic patients. Neuropsychobiology 36(4), 172-176 (1997).
68. Gupta S, Jain S, Brahmachari SK, Kukreti R. Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7(1), 31-47 (2006).
69. Nnadi CU, Malhotra AK. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr. Psychiatry Rep. 9(4), 313-318 (2007).
70. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am. J. Psychiatry 161(4), 700-706 (2004).
71. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 455(7210), 232-236 (2008).
72. Stone JL, O'Donovan MC, Gurling H et al. The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455(7210), 237-241 (2008).